Dennis D. Kim
Sr. VP, Corporate Development, Orexigen Therapeutics, Inc.
Companies
- CymaBay Therapeutics (United States)Chief Medical Officer May 17, 2021 to Apr 17, 20231
- Skye Bioscience, Inc.Chief Medical Officer Aug 23, 2019 to Aug 11, 20202
- Zafgen (United States)Chief Medical Officer Jun 18, 2014 to Jan 24, 20193
Holdings
Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.
Shares held
- CymaBay Therapeutics (United States)20,000 shares4Apr 17, 2023
As of each latest filing. The line shows shares held over time.
Recent filings
- Apr 17, 2023Sold 112,219 shares at $9.54 of CymaBay Therapeutics (United States)4
- Apr 17, 2023Exercised options 112,219 shares at $4.37 of CymaBay Therapeutics (United States)4
- Apr 13, 2023Sold 7,781 shares at $8.98 of CymaBay Therapeutics (United States)4
- Apr 13, 2023Exercised options 7,781 shares at $4.37 of CymaBay Therapeutics (United States)4
- Mar 28, 2023Sold 100 shares at $8.99 of CymaBay Therapeutics (United States)5
- Mar 28, 2023Exercised options 100 shares at $4.37 of CymaBay Therapeutics (United States)5
- Jan 19, 2022Bought 20,000 shares at $3.04 of CymaBay Therapeutics (United States)6
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5SEC EDGARForm 4 filed Mar 30, 2023
- 6SEC EDGARForm 4 filed Jan 20, 2022